TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
TBTC Study 25:A Prospective, Randomized, Double-Blind Study of the Tolerability of Higher Doses of Rifapentine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, Canada V5Z 4R4
- University of British Columbia
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, CANADA R3A 1R8
- University of Manitoba
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2P4Pq Canada
- Montreal Chest Institute McGill University
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Central Arkansas Veterans Health System
-
-
California
-
Los Angeles, California, United States, 90033
- LA County/USC Medical Center
-
San Francisco, California, United States, 94110
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Denver Department of Public Health and Hospitals
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20422
- Washington, D.C. VAMC
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Chicago VA Medical Center (Lakeside)
-
Hines, Illinois, United States, 60141
- Hines VA Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287-0003
- Johns Hopkins University School Of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
-
New Jersey
-
Newark, New Jersey, United States, 07107-3001
- New Jersey Medical School
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine
-
New York, New York, United States, 10037
- Harlem Hospital Center
-
New York, New York, United States, 10032
- Columbia University/Presbyterian Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center
-
Durham, North Carolina, United States, 34222
- Duke University Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212-2637
- Nashville VA Medical Center
-
-
Texas
-
Fort Worth, Texas, United States, 76107-2699
- University of North Texas Health Science Center
-
Houston, Texas, United States, 77009
- Thomas Street Clinic
-
San Antonio, Texas, United States, 78284
- Audi L. Murphy VA Hospital
-
-
Washington
-
Seattle, Washington, United States, 98104
- Seattle King County Health Department
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusions:
- Drug susceptible culture-positive tuberculosis
- Adequate induction therapy
- Age >18
- Normal screening labs
- Karnofsky >=60
- Informed consent
- Birth control if of child bearing potential
Exclusions:
- SilicoTB
- Skeletal or CNS TB
- Pregnant or breastfeeding
- Intolerance to INH or rifamycins
- Over 70 days TB treatment just prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Proportion of patients who fail to complete therapy in each of the dosing groups
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
1. Rate of serious adverse events in each of the dosing groups
|
|
2. Rate of total adverse events in each of the groups
|
|
3. Rate of relapse in patients with positive sputum culture at 2 months, in each of the groups
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Naomi Bock, MD, Centers for Disease Control & Prevention
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CDC-NCHSTP-2404
- 25
- HCK45
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.